Edwards Lifesciences Corporation $EW Stake Lessened by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. trimmed its position in Edwards Lifesciences by 8.6%, selling 62,269 shares and leaving a 664,187-share stake worth about $56.6 million (≈0.11% of the company).
• Edwards reported Q4 EPS of $0.58, missing the $0.62 consensus while revenue of $1.57 billion beat estimates and rose 13.3% year-over-year; the company set Q1 2026 guidance of $0.70–$0.76 EPS and analysts expect ~2.45 EPS for the year.
• Company insiders sold a total of 86,058 shares (≈$7.12 million) in the last quarter, while institutional investors own roughly 79.46% of the stock and analysts' average price target stands at $95.74 ("Moderate Buy").

Robeco Institutional Asset Management B.V. lessened its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 664,187 shares of the medical research company's stock after selling 62,269 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.11% of Edwards Lifesciences worth $56,622,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the third quarter worth $25,000. Dorato Capital Management bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth $29,000. True Wealth Design LLC increased its stake in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock worth $28,000 after buying an additional 259 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock worth $29,000 after buying an additional 302 shares during the last quarter. Finally, Hantz Financial Services Inc. increased its stake in shares of Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock worth $29,000 after buying an additional 164 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $78.02 on Tuesday. The company has a market cap of $44.98 billion, a PE ratio of 42.63, a P/E/G ratio of 2.03 and a beta of 0.95. The company has a fifty day moving average price of $81.32 and a two-hundred day moving average price of $82.06. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 12 month low of $68.63 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the prior year, the company posted $0.59 EPS. The firm's revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total value of $82,518.62. Following the sale, the vice president owned 33,934 shares of the company's stock, valued at $2,747,975.32. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 86,058 shares of company stock valued at $7,118,636 in the last quarter. Company insiders own 0.31% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on EW shares. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Barclays reaffirmed an "overweight" rating and issued a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 12th. Evercore reaffirmed an "outperform" rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 5th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $95.74.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.